Global Antibacterial Drugs Market to Exceed US $46 billion by 2015, According to New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a strategic global report on antibacterial drugs market. The world market for antibacterial drugs is projected to exceed US $46 billion by the year 2015. A constant rise in the proportion of elderly population, new therapies against resistant bacteria, and growing demand for Glycopeptides and Carbapenems are expected to drive market growth. Nevertheless, antibacterial drugs market in future is likely to be influenced by two key factors - antibiotic resistance and generic competition.

Antibacterial Drugs: A Global Strategic Business Report

Antibacterials treat an array of bacterial infections that range from minor to life threatening problems. High market maturity, patent expiries, generic drug penetration, and shortened product lifecycle due to bacterial drug resistance characterize the global market for antibacterial drugs. Patent expiries of several leading drugs in recent years have commoditized the market. In order to remain competitive, many players are extensively engaged in the development of anti-MRSA treatment, which can be used along with conventional antibacterials.

Asia-Pacific dominates the world anti-bacterial drugs market as stated by the new market research report on Anti-bacterial drugs. The region is forecast to also remain the fastest growing market in the coming years. Cephalosporins represents the largest segment in the global anti-bacterial drugs market. Macrolides is expected to be the fastest growing segment, driven by immunomodulatory effects and expanded indications.

Key players profiled in the report include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Daiichi Sankyo Co. Ltd., Elan Corp., Eli Lilly and Company, GlaxoSmithKline Plc, Hoffman-La Roche, Johnson & Johnson, Merck & Co., Pfizer Inc., Wyeth Pharmaceuticals Inc.

The report titled "Antibacterial Drugs: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a strategic review of anti-bacterial market trends, market drivers, market inhibitors, marketed drugs, patent expiries, clinical trials, product introductions/approvals, and recent industry activity. The study analyzes market data and analytics in terms of value sales for regions including The United States, Europe, Asia-Pacific, and Rest of World. The study analyzes market data and analytics in terms of value sales by drug classes, including Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and others.

For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Antibacterial_Drugs_Market_Report.asp

About Global Industry Analysts, Inc.:
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press(at)StrategyR(dot)com
Web Site http://www.StrategyR.com/

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website